Head-To-Head Review: TRACON Pharmaceuticals (TCON) versus Its Competitors
TRACON Pharmaceuticals (NASDAQ: TCON) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare TRACON Pharmaceuticals to similar businesses based on the strength of its risk, valuation, dividends, profitability, analyst recommendations, institutional ownership and earnings.
Insider & Institutional Ownership
34.1% of TRACON Pharmaceuticals shares are held by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 5.6% of TRACON Pharmaceuticals shares are held by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares TRACON Pharmaceuticals and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|TRACON Pharmaceuticals||$3.45 million||-$27.00 million||-2.50|
|TRACON Pharmaceuticals Competitors||$290.27 million||$35.99 million||52.51|
TRACON Pharmaceuticals’ competitors have higher revenue and earnings than TRACON Pharmaceuticals. TRACON Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of recent recommendations for TRACON Pharmaceuticals and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|TRACON Pharmaceuticals Competitors||948||3397||11901||239||2.69|
TRACON Pharmaceuticals currently has a consensus price target of $6.00, suggesting a potential upside of 96.72%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 41.54%. Given TRACON Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe TRACON Pharmaceuticals is more favorable than its competitors.
This table compares TRACON Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|TRACON Pharmaceuticals Competitors||-5,321.47%||-84.50%||-35.76%|
TRACON Pharmaceuticals competitors beat TRACON Pharmaceuticals on 7 of the 12 factors compared.
About TRACON Pharmaceuticals
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company’s lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.